Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06283251 · ClinicalTrials.gov registry record · NA

PediRISE Feasibility

A NA study of Pediatric Cancer and Financial Stress, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
4
Study locations

NCT06283251: Recruiting NA study of Pediatric Cancer and Financial Stress, sponsored by Dana-Farber Cancer Institute.

NCT06283251 is a NA study of Pediatric Cancer and Financial Stress that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 40 participants, below the 1,490-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06283251, a NA study of Pediatric Cancer and Financial Stress, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
4
Study locations

Study Summary

The goal of this research study is to learn whether investigators can successfully give the PediRISE program to families-in other words, whether most families are interested in participating in a study about the PediRISE program, including a 50-50 chance of receiving standard usual care, and a 50-50 chance of receiving the PediRISE support program. The names of the study groups in this research study are: * PediRISE Program Group * Usual Care Group

Primary Outcome

The proportion of eligible participants who provide informed consent to participate in the randomized guaranteed income intervention.

Interventions

  • BEHAVIORAL PediRISE Resource Program

Study Locations (4)

Massachusetts

  • Boston Children's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

California

  • University of California San Francisco - San Francisco

New York

  • Columbia University Medical Center - New York

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-05-15
Est. Completion 2027-06-30
Phase NA
Dana-Farber Cancer Institute

781 total trials

What NCT06283251 shows while recruiting

NCT06283251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,490-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (97% lower).

The record links to 4 conditions, with Pediatric Cancer appearing as the primary indexed condition, and to 1 intervention - of which PediRISE Resource Program is the first listed.

NCT06283251 reports a single indexed study location in Massachusetts, California, New York.

Frequently Asked Questions

What is clinical trial NCT06283251 about?

NCT06283251 is a clinical study titled "PediRISE Feasibility". The goal of this research study is to learn whether investigators can successfully give the PediRISE program to families-in other words, whether most families are interested in participating in a study about the PediRISE program, including a 50-50 chance of receiving standard usual care, and a 50-50...

What is the current status of trial NCT06283251?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-05-15. Estimated completion is 2027-06-30.

What conditions does trial NCT06283251 study?

This clinical trial studies the following conditions: Pediatric Cancer, Financial Stress, Financial Hardship, Disparities.

What interventions are being tested in trial NCT06283251?

The interventions under investigation include: PediRISE Resource Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06283251?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06283251 being conducted?

This trial has 4 study locations across California, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pediatric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06283251's enrollment target sits among peer trials

40 34th of 51 higher than 16 of 51 other Pediatric Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pediatric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06283251, the US trial registry maintained by the National Library of Medicine. NCT06283251 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.